These observations are also consistent with the premise that CD133 can be used to identify some cells with characteristics of ES-CSCs, although pathways classically associated with the CSC phenotype in other cancer types are also expressed in CD133-negative ES cells. This evidence concerns the gene PROM1 and cancer.